Empowered Funds LLC Buys 1,501 Shares of Edwards Lifesciences Co. (NYSE:EW)

Empowered Funds LLC raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,533 shares of the medical research company’s stock after acquiring an additional 1,501 shares during the period. Empowered Funds LLC’s holdings in Edwards Lifesciences were worth $1,890,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Alpha Financial Partners LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $693,000. Trust Co. of Vermont increased its holdings in shares of Edwards Lifesciences by 36.1% in the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock worth $199,000 after buying an additional 801 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Edwards Lifesciences by 10.6% in the 3rd quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company’s stock worth $992,000 after buying an additional 1,437 shares during the last quarter. Aaron Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $273,000. Finally, Net Worth Advisory Group bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $437,000. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on EW shares. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Robert W. Baird dropped their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $79.95.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock worth $2,002,829 in the last 90 days. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of EW opened at $76.23 on Friday. The company has a 50 day moving average price of $72.67 and a 200-day moving average price of $69.50. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a market capitalization of $44.96 billion, a PE ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Equities analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.